Agilawood silk quilt and manufacturing method thereof
阅读说明：本技术 一种沉香蚕丝被及制作方法 (Agilawood silk quilt and manufacturing method thereof ) 是由 潘嘉红 于 2020-07-08 设计创作，主要内容包括：本发明公开了一种沉香蚕丝被,包括外层100％纯棉提花布被套及内胆套,内胆套内胆填充桑蚕长丝和沉香胶囊,桑蚕长丝和沉香胶囊的体积比为99.5：0.5；沉香胶囊组分：沉香提取物20％-40％,水18％-26％,辛酰羟肟酸6％-10％,酵母提取物4％-8％,透明质酸钠5％-9％,金黄洋甘菊提取物6％-10％,丁二醇4％-8％,甘油3％-7％,燕麦肽5％-9％,葡聚糖0.30％-0.40％,丙二醇0.25％-0.35％,尿囊素0.02％-0.04％,卡波姆0.04％-0.08％,十三烷醇聚醚0.06％-0.10％,羟乙基纤维素0.01％-0.05％,生育酚0.03％-0.07％,烟酰胺0.05％-0.09％,三乙醇胺0.01％-0.05％。能显著缩短失眠患者的入睡潜伏期、提高睡眠效率、改善失眠严重程度；显著降低失眠患者的入睡前觉醒水平；显著改善抑郁、焦虑情绪。(The invention discloses an agilawood silk quilt, which comprises an outer-layer 100% pure cotton jacquard quilt cover and an inner container cover, wherein a mulberry silk filament and agilawood capsules are filled in the inner container of the inner container cover, and the volume ratio of the mulberry silk filament to the agilawood capsules is 99.5: 0.5; the agilawood capsule comprises the following components: 20-40% of agilawood extract, 18-26% of water, 6-10% of caprylyl hydroximic acid, 4-8% of yeast extract, 5-9% of sodium hyaluronate, 6-10% of golden yellow chamomile extract, 4-8% of butanediol, 3-7% of glycerol, 5-9% of oat peptide, 0.30-0.40% of glucan, 0.25-0.35% of propylene glycol, 0.02-0.04% of allantoin, 0.04-0.08% of carbomer, 0.06-0.10% of tridecanol polyether, 0.01-0.05% of hydroxyethyl cellulose, 0.03-0.07% of tocopherol, 0.05-0.09% of nicotinamide and 0.01-0.05% of triethanolamine. The sleep latency of the insomnia patients can be obviously shortened, the sleep efficiency is improved, and the insomnia severity is improved; the wakefulness level of the insomnia patients before falling asleep is obviously reduced; remarkably improve depression and anxiety.)
1. The utility model provides an agalloch eaglewood silk quilt, includes outer 100% pure cotton jacquard cloth quilt cover and inner bag cover, inner bag cover surface fabric adopts the preparation of Tewei strong non-woven fabrics, mulberry silk filament and agalloch eaglewood capsule are filled to inner bag of inner bag, contain the agalloch eaglewood in the agalloch eaglewood capsule and mix the liquid, the volume ratio of mulberry silk filament and agalloch eaglewood capsule is 99.5: 0.5; the agilawood mixed solution comprises the following components in percentage by weight: 20-40% of agilawood extract, 18-26% of water, 6-10% of caprylyl hydroximic acid, 4-8% of yeast extract, 5-9% of sodium hyaluronate, 6-10% of golden yellow chamomile extract, 4-8% of butanediol, 3-7% of glycerol, 5-9% of oat peptide, 0.30-0.40% of glucan, 0.25-0.35% of propylene glycol, 0.02-0.04% of allantoin, 0.04-0.08% of carbomer, 0.06-0.10% of tridecanol polyether, 0.01-0.05% of hydroxyethyl cellulose, 0.03-0.07% of tocopherol, 0.05-0.09% of nicotinamide and 0.01-0.05% of triethanolamine.
2. The agilawood silk quilt according to claim 1, is characterized in that: the agilawood capsule comprises the following components in percentage by weight: 30% of agilawood extract, 22% of water, 8% of caprylyl hydroximic acid, 6% of yeast extract, 7% of sodium hyaluronate, 8% of golden chamomile extract, 6% of butanediol, 5% of glycerol, 7% of oat peptide, 0.35% of glucan, 0.3% of propylene glycol, 0.03% of allantoin, 0.06% of carbomer, 0.08% of tridecyl alcohol polyether, 0.03% of hydroxyethyl cellulose, 0.05% of tocopherol, 0.07% of nicotinamide and 0.03% of triethanolamine.
3. The method for manufacturing agilawood silk quilt according to claim 1 or 2, comprising the following steps:
(1) the pure silkworm filament yarn is drawn by a pure manual and vertical and horizontal layering method;
(2) suturing of the liner sleeve: pressing by a high-frequency machine, and reserving a 90cm cotton filling opening;
(3) every time one layer is pulled, the agilawood capsules with the pre-calculated amount are uniformly sprinkled on the mulberry silk layer, and the layers are overlapped layer by layer;
(4) after the silk polishing blank is pulled according to the required specification and weight, silk is filled into a pre-pressed liner sleeve, and a reserved cotton filling opening is sealed by using a high-frequency machine;
(5) and filling the inner container into the quilt cover with the outer layer of high-count and high-density pure cotton jacquard cloth.
Technical Field
The invention relates to the technical field of household articles, in particular to a quilt and a manufacturing method thereof.
Background
With the rapid development of society, the living pace of people is accelerated, the working pressure is increased, the incidence rate of adult insomnia disorders is up to 10% -25%, and the adverse effects and social burden are increasingly serious. At present, the insomnia treatment mainly comprises drug treatment and non-drug treatment, the curative effect of the drug treatment is exact, but the adverse reaction is obvious after long-term application, and the non-drug treatment of the insomnia is gradually paid attention to nowadays. The book Ben Cao gang mu records that Chen Xiang is effective in treating abdominal pain, cholera and nausea, pathogenic qi chronic fever and refreshing mind. The agilawood has aromatic smell and enters the spleen, so that the body can be promoted to regulate the smell in the body, the circulation operation of air is promoted, people with smooth smell can easily relax, and the sleep can be improved. In aromatherapy, for example, a small number of research reports prove that lavender essential oil is effective in improving insomnia, and no report on the curative effect of agilawood for treating insomnia exists at present.
Disclosure of Invention
The invention provides an agilawood silk quilt capable of effectively treating insomnia and improving sleep quality and a manufacturing method thereof.
In order to achieve the purpose, the invention adopts the technical scheme that: the utility model provides an agalloch eaglewood silk quilt, includes outer 100% pure cotton jacquard cloth quilt cover and inner bag cover, and inner bag cover surface fabric adopts the preparation of Tewei strong non-woven fabrics, and the inner bag of inner bag cover is filled with mulberry silk filament and agalloch eaglewood capsule, contains the agalloch eaglewood mixed liquid in the agalloch eaglewood capsule, the volume ratio of mulberry silk filament and agalloch eaglewood capsule is 99.5: 0.5; the agilawood mixed solution comprises the following components in percentage by weight: 20-40% of agilawood extract, 18-26% of water, 6-10% of caprylyl hydroximic acid, 4-8% of yeast extract, 5-9% of sodium hyaluronate, 6-10% of golden yellow chamomile extract, 4-8% of butanediol, 3-7% of glycerol, 5-9% of oat peptide, 0.30-0.40% of glucan, 0.25-0.35% of propylene glycol, 0.02-0.04% of allantoin, 0.04-0.08% of carbomer, 0.06-0.10% of tridecanol polyether, 0.01-0.05% of hydroxyethyl cellulose, 0.03-0.07% of tocopherol, 0.05-0.09% of nicotinamide and 0.01-0.05% of triethanolamine.
Further, the agilawood silk quilt comprises the agilawood capsule components in percentage by weight: 30% of agilawood extract, 22% of water, 8% of caprylyl hydroximic acid, 6% of yeast extract, 7% of sodium hyaluronate, 8% of golden chamomile extract, 6% of butanediol, 5% of glycerol, 7% of oat peptide, 0.35% of glucan, 0.3% of propylene glycol, 0.03% of allantoin, 0.06% of carbomer, 0.08% of tridecyl alcohol polyether, 0.03% of hydroxyethyl cellulose, 0.05% of tocopherol, 0.07% of nicotinamide and 0.03% of triethanol fat.
The efficacy and the function of various components of the agilawood capsule are as follows:
the efficacy of the agilawood extract is as follows: can effectively improve insomnia symptoms, has the effects of relieving flatulence, maintaining beauty and keeping young, discharging stubborn stool, waist and knee deficiency cold, removing grease, belch and vomitting, cardiac and abdominal pain, large intestine stagnation of qi, chest and diaphragm stuffiness and asthma and the like, and also has good effects of warming kidney, receiving qi and supporting yang.
Efficacy and action of caprylhydroxamic acid: the caprylyl hydroximic acid has excellent antibacterial and bacteriostatic properties on skin.
Efficacy and action of yeast extract: contains many nutrients, such as vitamins, amino acids, polysaccharides, trace elements, etc., and the existence of these nutrients provides the yeast extract with various effects.
The efficacy and effect of sodium hyaluronate: the sodium hyaluronate has effects of moistening skin, nourishing skin, repairing and preventing skin injury, lubricating property, film forming property, thickening property and wrinkle resistance.
The efficacy and effect of the golden chamomile extract are as follows: has good effects of relieving allergy, repairing sensitive skin, reducing thin red blood streak, reducing redness, regulating uneven skin color, etc.
Efficacy and action of butanediol: can be used as humectant and solvent.
Glycerol efficacy and action: it can be used as lubricant and solvent, and also has skin caring and humectant effects.
Oat peptide efficacy and action: the oat peptide is also called as small molecular active peptide, has ultrahigh nutritional value, can effectively regulate the physiological balance of people, and ensures that eight systems of the human body can orderly operate. The small molecule active peptide can provide better collagen for skin, improve the environment of skin cells, promote metabolism, make skin more smooth and moist, and effectively delay skin aging. Has strong repairing capability, has peculiar repairing effect on scars on the body and ensures that the skin is smoother and more elastic. And has strong moisture absorption effect.
Dextran efficacy and effect: enhancing the self-protection ability of skin, improving the immunity of skin and eliminating free radicals. Activating skin cells, promoting collagen synthesis, and improving skin elasticity. Excellent antiallergic effect. Has excellent anti-inflammatory effects such as acne suppression, acne suppression and the like. Has excellent sunscreen effect on skin, and can enhance the capability of resisting ultraviolet rays of skin.
Propylene glycol efficacy and action: used as an extraction solvent.
Allantoin efficacy and action: allantoin is an amphoteric compound, can combine with multiple substances to form double salt, has effects of protecting from light, sterilizing, preventing corrosion, relieving pain, resisting oxidation, and keeping skin moisture, moistening and softening.
Carbomer efficacy and action: protecting skin, reducing irritation, and preventing various allergic symptoms. Diminishing inflammation and sterilizing.
Tridecyl polyether-6 efficacy and action: can be used as emulsifier, surfactant, and emollient.
Hydroxyethyl cellulose efficacy and action: can be used as antiseptic, emulsifier, binder and thickener.
Tocopherol efficacy and action: is used as antioxidant.
Niacinamide efficacy and action: reducing and preventing dullness, hair 4102 yellows and vegetable colors of skin 5261 during early aging; repairing damaged stratum corneum lipid 1653 barrier, and improving skin resistance; the deep layer has the effect of locking water, and the skin is supplemented with water; pores are narrowed and the severity of acne is reduced; niacinamide enhances skin barrier function by increasing ceramide content in the stratum corneum, reducing transdermal water loss.
Triethanolamine efficacy and action: used as emulsifier, humectant, moisturizer, thickener, and pH balancer. The triethanolamine is neutralized with carboxyl of carbomer to form a stable high molecular structure, so that the application effects of thickening and moisturizing are achieved.
A manufacturing method of agilawood silk quilt comprises the following steps:
(1) the pure silkworm filament yarn is drawn by a pure manual and vertical and horizontal layering method;
(2) suturing of the liner sleeve: pressing by a high-frequency machine, and reserving a 90cm cotton filling opening; in the traditional sewing, a needle of a sewing machine can damage the surface of the fabric to form a needle hole, and the waterproof and anti-seepage effects cannot be achieved.
(3) Every time one layer is pulled, the agilawood capsules with the pre-calculated amount are uniformly sprinkled on the mulberry silk layer, and the layers are overlapped layer by layer;
(4) after the silk polishing blank is pulled according to the required specification and weight, silk is filled into a pre-pressed liner sleeve, and a reserved cotton filling opening is sealed by using a high-frequency machine;
(5) and filling the inner container into the quilt cover with the outer layer of high-count and high-density pure cotton jacquard cloth.
The liner fabric of the invention adopts DuPont paper and has the characteristics that: green and environment-friendly, and pure components (100% polyethylene); high-density waterproof and breathable: (the fineness of the monofilament can reach 0.5 micron), which is beneficial to the lasting emission of the fragrance of the agilawood; after the agilawood capsule is exploded by pressure, the risk that the overflowing agilawood essential oil possibly permeates into the cloth surface of the inner container and then is stained on the outer-layer pure cotton quilt cover to cause local yellowing of the outer-layer fabric is reduced to the maximum extent.
The invention has the beneficial effects that: the insomnia patients using the agilawood silk quilt can obviously shorten the sleep latency period of the insomnia patients, improve the sleep efficiency and improve the insomnia severity; the wakefulness level of the insomnia patients before falling asleep is obviously reduced; the depression and anxiety mood of the insomnia patient are obviously improved; the insomnia curing medicine has no obvious difference on gender, and has better effect when the age is less than 50 years old.
Drawings
FIG. 1 is a graph showing the coordinate change of sleep efficiency (SLEEP EFFICIENCY) of the experimental group using the agarwood silk quilt of the present invention and the control group using the non-agarwood silk quilt for 3 weeks;
FIG. 2 is a graph showing the variation coordinates of the sleep onset latency (SLEEP LATENCY) of 3 weeks of treatment using the experimental group using the agarwood silk quilt of the present invention and the control group using the non-agarwood silk quilt;
FIG. 3 is a graph showing the coordinate change of wake before sleep (PSAS) of the experimental group using the Aquilaria sinensis quilt and the control group using the non-Aquilaria sinensis quilt for 3 weeks according to the present invention;
FIG. 4 is a graph showing the change coordinates of Insomnia Severity Index (ISI) for 3 weeks of treatment using an experimental group using an agilawood silk quilt according to the present invention and a control group using a non-agilawood silk quilt;
FIG. 5 is a schematic diagram showing the change coordinates of anxiety index (GAD-7) of insomnia patients treated for 3 weeks by the experimental group using the agilawood silk quilt of the present invention and the control group using the non-agilawood silk quilt;
FIG. 6 is a schematic diagram showing the change coordinates of depression (PHQ-9) in insomnia patients treated for 3 weeks with the experimental group using an agilawood silk quilt according to the present invention and the control group using a non-agilawood silk quilt;
FIG. 7 is a graph showing a comparison of sleep quality index (PSQI) sex differences between the 3 weeks of treatment of the experimental group using the agilawood silk quilt according to the present invention;
FIG. 8 is a comparison between sex and sleep efficiency (SLEEP EFFICIENCY) of the experimental group treated with the agilawood silk quilt for 3 weeks according to the present invention;
FIG. 9 is a schematic diagram showing the sex difference comparison of the sleep onset latency (SLEEP LATENCY) of 3 weeks of treatment in the experimental group using the agilawood silk quilt of the present invention;
FIG. 10 is a schematic diagram showing the comparison of sex differences between the awakenings before falling asleep (PSAS sex differences)) of the experimental group treated with the agilawood silk quilt of the present invention for 3 weeks;
FIG. 11 is a graph showing the comparison of the gender difference of Insomnia Severity Index (ISI) in the experimental group treated for 3 weeks using the agilawood silk quilt of the present invention;
FIG. 12 is a schematic diagram showing the comparison of the sex difference of anxiety index (GAD-7) in the experimental group treated with the agilawood silk quilt for 3 weeks according to the present invention;
FIG. 13 is a comparison of depression (PHQ-9) sex difference between insomnia patients treated for 3 weeks with the experimental group of agilawood silk quilt of the present invention;
FIG. 14 is a schematic diagram showing the comparison of sex difference of sleep quality (PSQI) of the experimental group treated for 3 weeks using the agilawood silk quilt according to the present invention;
FIG. 15 is a graph showing the comparison of the sleep efficiency (SLEEPEFFICIENCY) of the experimental group of the present invention using the agilawood silk quilt for 3 weeks at different age groups;
FIG. 16 is a comparative schematic diagram of the sleep onset latency (SLEEP LATENCY) of 3 weeks of treatment in different age groups of experimental groups using agilawood silk quilt of the present invention;
FIG. 17 is a graph showing a comparison of sleep quality (PSQI) index for 3 weeks of treatment in different age groups of experimental groups using agilawood silk quilt according to the present invention;
FIG. 18 is a comparative graph showing the severity index of insomnia (ISI) of the experimental group of the present invention using Aquilaria silk quilt for 3 weeks at different age groups;
FIG. 19 is a graph showing the comparison of anxiety index (GAD-7) of the experimental group using the agilawood silk quilt of the present invention for 3 weeks at different age groups;
FIG. 20 is a comparative schematic view showing the treatment of depression (PHQ-9) for 3 weeks at different age groups in the experimental group using the agilawood silk quilt of the present invention;
FIG. 21 is a table showing the indexes of the experimental group using the agilawood silk quilt according to the present invention for 3 weeks at different ages.
Detailed Description
In order to make the object and technical solution of the present invention more apparent, the present invention will be further described in detail with reference to the following examples.
The invention relates to an agilawood silk quilt which structurally comprises an
In the preferred embodiment of the invention, the agilawood capsule comprises the following components in percentage by weight: 30% of agilawood extract, 22% of water, 8% of caprylyl hydroximic acid, 6% of yeast extract, 7% of sodium hyaluronate, 8% of golden yellow chamomile extract, 6% of butanediol, 5% of glycerol, 7% of oat peptide, 0.35% of glucan, 0.3% of propylene glycol, 0.03% of allantoin, 0.06% of carbomer, 0.08% of tridecyl alcohol polyether, 0.03% of hydroxyethyl cellulose, 0.05% of tocopherol, 0.07% of nicotinamide and 0.03% of triethanolamine.
The invention relates to a method for manufacturing agilawood silk quilt, which comprises the following steps:
(1) the pure silkworm filament yarn is drawn by a pure manual and vertical and horizontal layering method;
(2) suturing of the liner sleeve: pressing by a high-frequency machine, and reserving a 90cm cotton filling opening;
(3) every time one layer is pulled, the agilawood capsules with the pre-calculated amount are uniformly sprinkled on the mulberry silk layer, and the layers are overlapped layer by layer;
(4) after the silk polishing blank is pulled according to the required specification and weight, silk is filled into a pre-pressed liner sleeve, and a reserved cotton filling opening is sealed by using a high-frequency machine;
(5) and filling the inner container into the quilt cover with the outer layer of high-count and high-density pure cotton jacquard cloth.
In view of the present invention, the applicant made clinical trials of therapeutic efficacy, including the criteria of the panelists:
A. age 18-65 years; B. male and female are not limited; C. the diagnosis of the primary insomnia is consistent with ICSD-3; D. the purpose and content of the trial was clearly understood and informed consent was voluntarily signed.
Exclusion criteria:
A. for patients allergic to lignum Aquilariae Resinatum;
B. history of dependence on opiates, amphetamines and other addictive drugs;
C. obstructive sleep apnea-hypopnea syndrome, idiopathic excessive sleepiness, and other sleep disorders;
D. other neurological and psychiatric disorders are combined;
E. serious complications of heart, brain, kidney, liver, lung, hematopoietic system and other important organs;
F. pregnant, lactating women or recent european birth schemes;
G. taking medicines affecting sleep, such as benzodiazepines, melatonin, antihistamine, anxiolytic and antidepressant medicines, etc. 2 weeks before the administration;
H. participating in other clinical tests in the last 3 months;
I. other conditions lead to patients who are not eligible to participate in the clinical trial.
The research process is as follows:
insomnia patients meeting the inclusion and exclusion criteria were randomly divided into experimental groups (80 cases) using agilawood silk quilts and control groups (40 cases) using silk quilts without agilawood capsules using random number expression.
Adjusting indoor temperature to 15-20 deg.C with air conditioner, covering the experimental group with lignum Aquilariae Resinatum silk quilt, covering the control group with quilt without lignum Aquilariae Resinatum capsule, and treating for 3 weeks under the same living conditions.
Evaluation indexes are as follows: sleep efficiency (SLEEP EFFICIENCY) and sleep onset latency (SLEEP LATENCY) were calculated from entries in the insomnia severity Index Scale (ISI), the Pre-sleep arousal scale (PSAS), the Depression screening scale (PHQ-9), the generalized anxiety scale (GAD-7), the Pittsburgh sleep quality index scale (PSQI).
The patient fills the scales on the network platform at the baseline,
Quality control: and uniformly packaging and labeling the agilawood silk quilt and the non-agilawood silk quilt. Checking by a specially-assigned person, recording the packaging process, keeping and distributing by the specially-assigned person, and recording the detailed record of each distribution treatment.
Treatment groups were dropped in 12 cases for a total of 68 people inclusion analysis; 4 cases of the control group are dropped, 36 cases are included and analyzed, and the statistical method adopts SPSS13.0 statistical software for analysis; the measurement data is represented by mean and standard deviation, and the count data is represented by X2Checking; the curative effect ratio between the two groups adopts a two-factor variance analysis of repeated measurement; the test level α is 0.05. The difference between the two groups has no statistical significance (P) in sex, age, education degree, marital status, tobacco, wine and tea usage>0.05)。
The experimental results are as follows:
in 3 weeks, the experimental group using the agilawood silk quilt was a solid line, and the silk quilt control group without the agilawood capsules was a dotted line, and as shown in fig. 1, the experimenter using the agilawood silk quilt significantly improved the sleep efficiency as a comparison of the experimental results. As shown in fig. 2, experimenters using agilawood silk quilt significantly shortened the sleep-onset latency of insomnia patients. As shown in fig. 3, experimenters using agilawood silk quilt significantly reduced the level of wakefulness before sleep in insomnia patients. As shown in fig. 4, treatment of experimenters using agilawood silk quilt significantly reduced the insomnia severity index of insomnia patients. As shown in fig. 5, experimenters using agilawood silk quilt significantly improved anxiety index of insomnia patients. As shown in fig. 6, treatment of experimenters using agilawood silk quilt significantly improved the depressive index of insomnia patients.
In the experimental group using the agilawood silk quilt within 3 weeks, the triangles represent boys, the circles represent girls, and as shown in fig. 7, compared with a Pittsburgh sleep quality index table (PSQI), the effect of significantly improving the sleep quality of insomnia patients treated by the experimenter using the agilawood silk quilt is not gender different. As shown in fig. 8, the experimenters using the agilawood silk quilt had no gender difference in sleep efficiency (SLEEP EFFICIENCY). As shown in fig. 9, the experimenters using the agilawood silk quilt had no sex difference in sleep latency (SLEEP LATENCY). As shown in fig. 10, experimenters using the agilawood silk quilt had no sex difference in awakening before falling asleep (PSAS). As shown in fig. 11, experimenters using agilawood silk quilts had no gender difference in Insomnia Severity Index (ISI). As shown in FIG. 12, the experimenters using the Aquilaria sinensis silk quilt were anxious (GAD-7) without sex differences.
1 for 21-30 years, 2 for 31-40 years, 3 for 41-50 years, and 5 for greater than or equal to 50 years. As shown in fig. 13 to 20, the subjects using the agilawood silk quilt generally showed improvement in most of the indicators of the population less than or equal to 50 years old, and only in the sleep efficiency and the sleep severity of the population more than 50 years old. As shown in FIG. 21, the present invention is a table showing the indexes of the experimental groups using the agilawood silk quilt for 3 weeks at different ages.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention and are intended to be equivalent replacements within the scope of the present invention.
- 上一篇：一种医用注射器针头装配设备
- 下一篇：一种手袋加工用的自动定位装饰线压制装置